ANI Pharmaceuticals' ILUVIEN hits both endpoints in chronic uveitis Phase 4 trial
The SYNCHRONICITY trial showed a 3.6-letter vision gain and a 157.5-micron drop in retinal thickness at six months, backing ILUVIEN's use in retina practices already prescribing it.
Executive Summary
- A Phase 4 trial of an already-marketed corticosteroid implant met both of its co-primary vision and anatomic endpoints at six months, reinforcing the drug's established use in a chronic eye inflammation that has previously responded to steroid treatment.
- Because the drug is already approved and used in this setting, the result functions as confirmation of a known effect rather than a test of a new mechanism, holding the treatment to its own established response band.
- The adverse event pattern, dominated by intraocular pressure elevation and cataract, tracked prior experience with this implant class, the expected trade-off of sustained intravitreal corticosteroid delivery.
- No other industry-sponsored trial is currently testing a Glucocorticoid Receptor agonist in this specific chronic uveitis population, leaving this readout as a single-sponsor data point rather than part of a competitive readout cycle.
The result
ANI Pharmaceuticals announced on July 13, 2026 that the intent-to-treat population of 108 patients in SYNCHRONICITY (NCT05322070) showed a mean gain of 3.6 letters in best corrected visual acuity, measured by the ETDRS chart, at six months compared with baseline (p<0.0077), moving the average score from 62.5 to 65.8 letters. The same population showed a mean reduction of 157.5 microns in central subfield thickness, measured by SD-OCT, from 505.7 microns at baseline to 348.8 microns at month 6 (p<0.0001). Both were the trial's registered co-primary endpoints, change in BCVA and change in CST. ANI+1ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, ...Jul 13, 2026Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment UveitisNCT05322070
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
How it was done
SYNCHRONICITY is a prospective, open-label, single-arm study with no comparator arm, enrolling adults with active, recurrent chronic non-infectious posterior segment uveitis that had previously responded to localized corticosteroid treatment. Patients received a single 0.18 mg fluocinolone acetonide intravitreal implant in the study eye and were followed for 24 months; the co-primary endpoints were assessed at the six-month mark in the 108-patient intent-to-treat population. The trial began enrollment in June 2022, moved to Active, not recruiting status in August 2024, and set a primary completion date of November 1, 2025. ANI+1ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, ...Jul 13, 2026Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment UveitisNCT05322070
Safety and tolerability
Treatment-related adverse events occurred in 29% of the 108-patient safety population, with ocular hypertension in 6% (7 patients) and cataract in 5% (5 patients) as the most common. Separately, 18% of patients (19 of 108) had an intraocular pressure increase of 25 mmHg or more, and 7% (8 of 108) required a laser or surgical procedure to lower intraocular pressure. ANI Pharmaceuticals said these adverse events were consistent with prior trials of the fluocinolone acetonide intravitreal implant, the expected tolerability profile for a sustained-release corticosteroid delivered directly into the eye. ANIANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, ...Jul 13, 2026
Competitive and regulatory context
No other industry-sponsored trial is currently registered studying a Glucocorticoid Receptor agonist in this indication, and the broader Glucocorticoid Receptor target field spans distant indications such as asthma, multiple myeloma, and Cushing syndrome rather than direct competitors in chronic uveitis. ILUVIEN is already an established treatment for chronic NIU-PS, so the readout functions as confirmation of the drug's known effect in a population its principal investigator described as seen "every day" in retina practices, rather than a test of a new therapeutic hypothesis. ANI Pharmaceuticals said detailed results and additional analyses will be presented at medical conferences in the fourth quarter of 2026. ANIANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, ...Jul 13, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.